Gaëlle Pierron

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis

Emmanuel Barillot, Gudrun Schleiermacher, Isabelle Janoueix-Lerosey, 2013, PloS one.

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Gudrun Schleiermacher, Isabelle Janoueix-Lerosey, Olivier Delattre, 2008, Nature.

Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.

Olivier Delattre, Birgit Geoerger, D. Surdez, 2012, Cancer research.

A prognostic DNA signature for T1T2 node‐negative breast cancer patients

Anne Vincent-Salomon, Bernard Asselain, Olivier Delattre, 2010, Genes, chromosomes & cancer.

Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma

Emmanuel Barillot, Gudrun Schleiermacher, Philippe Hupé, 2005, Cell cycle.

Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas

Roman Rouzier, Anne Vincent-Salomon, Guillem Rigaill, 2013, PloS one.

Two types of chromosome 1p losses with opposite significance in gliomas

Olivier Delattre, Caroline Brennetot, Alain Aurias, 2005, Annals of neurology.

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas

Emmanuel Barillot, Jean-Yves Delattre, Olivier Delattre, 2007, International journal of cancer.

Accumulation of segmental alterations determines progression in neuroblastoma.

Gudrun Schleiermacher, Jérôme Couturier, Isabelle Janoueix-Lerosey, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

Mauro Delorenzi, Jean-Paul Concordet, Olivier Delattre, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials

Roman Rouzier, Etienne Rouleau, Nicolas Servant, 2015, Journal of the National Cancer Institute.